As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

The As­traZeneca-Alex­ion megamerg­er re­ceived a good sign Fri­day, de­spite warn­ing signs of the tides turn­ing against large M&A phar­ma deals.

US reg­u­la­tors at the FTC …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.